AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT05872958
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1426
- Registration Number
- NCT05866276
- Locations
- 🇮🇩
Research Site, Surabaya, Indonesia
🇮🇩Perisai Husada, Bandung, Jawa Barat, Indonesia
🇻🇳Nguyen Tri Phuong Hospital, Ho Chi Minh City, Vietnam
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT05864391
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: BGF (budesonide/glycopyrrolate/formoterol fumarate)
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT05862545
- Locations
- 🇮🇹
Research Site, Verona, Italy
Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: HFA MDIDrug: HFO MDI
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT05850494
- Locations
- 🇺🇸
Research Site, El Paso, Texas, United States
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- Biological: GC012F (AZD0120)
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT05850234
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT05848440
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy
Withdrawn
- Conditions
- PregnancyPregnant WomenPregnancy Outcome
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05847140
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Active, not recruiting
- Conditions
- Biliary Tract Cancer
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 235
- Registration Number
- NCT05835778
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Phase 3
Active, not recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05835310
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath